

PFF Summit 2023: Academic Abstracts

Sub Program	Proposal Title	Lead Institution Name	Submitting Author	Applicant Highest Degree(s)	Applicant Other Degree(s)	Applicant Email	Additional Notes
Academic	Microaspiration Related Interstitial Fibrosis (MARIF)		Alexandre Fabro	MD	PhD	fabro@fmp.usp.br	
Academic	Barriers and Facilitators to Care for Rural Populations with Interstitial Lung Disease: Perspectives from Pulmonary Fibrosis Foundation Care Center Network Providers	The Regents of the University of California, San Francisco	Alison M. DeDent	M.D.	B.S.	alison.dedent@ucsf.edu	
Academic	Perceptions of Pulmonary Fibrosis Foundation Care Center Network Providers Caring for Rural Patients with Interstitial Lung Disease	The Regents of the University of California, San Francisco	Alison M. DeDent	M.D.	B.S.	alison.dedent@ucsf.edu	
Academic	Understanding unmet needs in the pulmonary fibrosis community through help center inquiries	Piedmont Healthcare	Amy Hajari Case	M.D.	B.S.	ashajari@gmail.com	
Academic	Trajectories of health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF)	Boehringer Ingelheim Pharmaceuticals, Inc.	Amy Olson	M.D.	M.S.P.H.	amy.olson@boehringer-ingelheim.com	
Academic	Differences in Healthcare Utilization at the End of Life: a Comparison Study of Lung Cancer, Chronic Obstructive Pulmonary Disease, and Idiopathic Pulmonary Fibrosis	University of California San Francisco School of Medicine	Angela Suen	MD		angela.suen@ucsf.edu	
Academic	Association of HRCT patterns and transplant free survival in patients with progressive fibrosing interstitial lung diseases (ILDs) in the ILD-PRO Registry	Duke University School of Medicine	Aparna Swaminathan	MD		aparna.swaminathan@duke.edu	
Academic	Feasibility of a Telehealth-Delivered Breathing Intervention for Patients with Idiopathic Pulmonary Fibrosis	Arizona Board of Regents, University of Arizona	Aubree Carlson	Ph.D.	M.S.N., B.S.N., B.S.	aubcarlson@gmail.com	
Academic	Impact of Envisia Genomic Classifier on Clinical Outcomes in Patients with Interstitial Lung Disease	UCLA David Geffen School of Medicine, Los Angeles	Augustine Chung	M.D.	M.H.S.	achung@mednet.ucla.edu	
Academic	Non-Tobacco Exposures in Combined Pulmonary Fibrosis and Emphysema Across ILDs: A Case-Control Analysis	The University of Chicago	Cathryn Lee	MD		clee15@uchicago.edu	
Academic	Cigarette Smoking and Risk of Interstitial Lung Disease Diagnosis: A Systematic Review and Meta-Analysis	The University of Chicago	Cathryn Lee	MD		clee15@uchicago.edu	
Academic	Extracellular Matrix Mechanosignaling Regulates Macrophage Immunometabolism in Pulmonary Fibrosis	University of Alabama at Birmingham	Chao He	MD	PhD	jeffrey.chao.he@gmail.com	2nd Place
Academic	Clinical Telomere Length Testing for Interstitial Lung Disease: Diagnostic Utility and Impact on Clinical Management	The Trustees of Columbia University in the City of New York	Da Zhang	M.D.	B.S.	dz2409@cumc.columbia.edu	3rd Place
Academic	Post hoc pooled analyses of open-label and randomized controlled trials of senolytics dasatinib and quercetin in Idiopathic Pulmonary Fibrosis	University of Texas Health Science Center at San Antonio (UT Health San Antonio)	Dean Kellogg	MD		kelloggdl@uthscsa.edu	
Academic	Impact of Resources in Reducing Depression in Patients with Chronic Fibrosing Interstitial Lung Disease	University of Arizona	Elysia Tjong	D.O.	B.S.	elysijatjong@arizona.edu	
Academic	Cura personalis: Bringing care to the whole person with idiopathic pulmonary fibrosis	Loyola University Medical Center	Erica Dixon-Johnson	BSN	BS	dixon.ericac@gmail.com	
Academic	Remote patient monitoring for managing interstitial lung disease in hybrid health care models: a mixed methods process	University of California, San Francisco (Reagents UCSF Contracts and Grants)	Genevieve Gillett	B.A.	3	genevieve.gillett@ucsf.edu	
Academic	Uncertainty, Coping, and Genetic Assessment among Close Relatives of People with Familial Pulmonary Fibrosis	Vanderbilt University Medical Center (VUMC)	Janet Talbert	MS	BS	janet.talbert@vumc.org	

Academic	"TAKING A DEEP BREATH: ASSESSING THE BENEFITS AND CHALLENGES OF SUPPORT GROUPS FOR PATIENTS LIVING WITH PULMONARY FIBROSIS AND THEIR CARE PARTNERS"		Jennifer Wescoe	M.Ed.	B.S.	jennifer@wescoe.org	
Academic	Evaluating risk factors for development of interstitial lung disease in long COVID patients with or without pre-existing interstitial lung disease	Tampa General Hospital affiliated with the University of South Florida	Jorden Eileen Smith	M. D.	A. S., B. S.	jordensmith@usf.edu	
Academic	EMR-Based Approach to a Geographic Comparison of Statewide Rates of Antifibrotic Treatment and Proximity to PFF Care Centers in the IPF Population over age		Kelly Tarcza		B.S.	kelly.tarcza@sluhn.org	
Academic	Fibrotic precision-cut lung slices for assessment of radiolabeled probe targeting	University of Wisconsin-Madison (Board of Regents University of Wisconsin System)	Kristen Stott	B.S. in progress		kristenstott@gmail.com	
Academic	Cu-64-PEG-FUD for non-invasive detection of murine-induced pulmonary fibrosis	University of Wisconsin-Madison (Board of Regents University of Wisconsin System)	Ksenija Bernau	PhD	M.S., B.S.	kbernau@medicine.wisc.edu	1st Place
Academic	Metabolic and Epigenetic Characterization of the Distal Alveolar Epithelium in the Sftpc173T Murine Model of IPF	University of Pennsylvania, School of Veterinary Medicine	Luis Rodriguez	PhD		luis.rodriguez@pennmedicine.upenn.edu	
Academic	Environmental exposures are associated with increased risk of progressive preclinical familial pulmonary fibrosis	Vanderbilt University Medical Center (VUMC)	Margaret Louise Salisbury	M.D.	M.S., B.S.	margaret.salisbury@vumc.org	Honorable Mention
Academic	Piezo2 is an important mechano-receptor in pulmonary fibrosis	Virginia Commonwealth University	Margaret Thomas Freeberg	Ph.D	B.S., M.S.	margaret.freeberg@vcuhealth.org	Honorable Mention
Academic	Post-Tuberculous Lung Disease and Fibrosis in a Ugandan Cohort		Peter Jackson	MD			
Academic	Biodistribution of inhaled AD-214 in a sheep model of lung fibrosis – a proof of concept study	Federation University Australia	Robert Bischof			r.bischof@federation.edu.au	
Academic	Inhibition of poly (ADP-Ribose) polymerase attenuates bleomycin-induced pulmonary fibrosis in a sheep model	Federation University Australia	Robert Bischof			r.bischof@federation.edu.au	
Academic	Rural Telehealth Monitoring in Patients with Interstitial Lung Disease: Bringing Care Delivery to those with Reduced Access		Ryan Boente	MD			
Academic	Early molecular pathways triggers for post-COVID-19 fibrosis	Ribeirão Preto Medical School, University of São Paulo	Sabrina Setembre Batah			sabrina7batah@gmail.com	
Academic	Dendritic cells as a novel potential biomarker In Airway-Centered Interstitial Fibrosis	University of Sao Paulo (Universidade de São Paulo), USP	Sabrina Setembre Batah			sabrina7batah@gmail.com	
Academic	Whole-transcriptome sequencing reveals distinct molecular pathways between MARIF and f-HP	Ribeirão Preto Medical School, University of São Paulo	Sabrina Setembre Batah			sabrina7batah@gmail.com	
Academic	Practice Patterns for Screening and Treating ILD-related PH at Specialty Care Centers in the United States		Sarah Khan	MD	AB	slkhan049@gmail.com	
Academic	A Unique EMR-Based Review of US Demographic Trends in Antifibrotic Treatment of IPF Patients by Age, SES.	St. Luke's Hospital & Health Network	Sophia Perrotta		B.S.	sophia.perrotta@sluhn.org	
Academic	Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease	Inova Fairfax Hospital	Steven Nathan	M.D.		Steven.Nathan@inova.org	
Academic	A Low FVC/DLCO Ratio Helps Increase Clinical Suspicion For Fibrotic HP Over IPF	University of Texas Health Science Center at San Antonio (UT Health San Antonio)	Tannam Vongvittapana	B.S.		seanvong22@gmail.com	
Academic	Nicotine Affects Mitochondrial Dynamics in Human Airway Smooth Muscle Cells		Zheng Mengning			Zheng.Mengning@mayo.edu	
Academic	STIM1-Orai1 Pathway Mediates Mechanical Strain-induced Airway Smooth Muscle Remodeling by Crosstalk with Piezo		Zheng Mengning			Zheng.Mengning@mayo.edu	
Academic	Mechanosensitive Ion Channel Piezo Mediates Mechanical Stretch-induced Airway Remodeling in Human Lung	Mayo Clinic	Zheng Mengning			Zheng.Mengning@mayo.edu	

PFF Summit 2023: Industry Abstracts

Sub Program	Proposal Title	Submitting Author	Applicant Highest Degree(s)	Applicant Other Degree(s)	Applicant Email
Industry	Translational value of bleomycin model: new insights to guide drug discovery for IPF	Annalisa Murgio	B.D.		a.murgio@chiesi.com
Industry	Development and Validation of Case-Finding Algorithms for Use in Secondary Electronic Health Databases to Identify Patients with Fibrotic Interstitial Lung	Ariel Berger			ariel.berger@evidera.com
Industry	Factors Associated with Delayed Diagnosis of Fibrotic Interstitial Lung Disease (ILD)	Ariel Berger			ariel.berger@evidera.com
Industry	Assessment of the oxygen therapy initiation and use in patients with fibrotic interstitial lung disease	Joseph Yang	PharmD	B.S., M.S.	joseph.yang@boehringer-ingelheim.com
Industry	Interim analysis of AIR - an open-label, single-arm, 36-week, Phase 2 trial of the angiotensin type 2 receptor agonist (ATRAG), C21, in individuals with IPF	Asa Magnusson	BBA		asa.magnusson@vicorepharma.com
Industry	A personalized treatment for anxiety and challenges of living with Pulmonary Fibrosis	Asa Magnusson	BBA		asa.magnusson@vicorepharma.com
Industry	ASPIRE – a patient friendly trial evaluating the reparatory potential of C21 in IPF	Asa Magnusson	BBA		asa.magnusson@vicorepharma.com
Industry	Real-World Healthcare Resource Utilization Before and After Initiation of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Interstitial Lung	Benjamin Wu	PharmD	MS	bwu@unither.com
Industry	People Living with Idiopathic Pulmonary Fibrosis (IPF) in the Internet Age: US Qualitative Study	Camilla Graham	MD	PhD	camilla.graham@puretechhealth.com
Industry	Improvement in HRCT lung fibrosis with inhaled pirfenidone is associated with better health-related quality of life scores in patients with idiopathic pulmonary fibrosis	Deepthi Nair			dnair@avalynpharma.com
Industry	Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients?	Deepthi Nair			dnair@avalynpharma.com
Industry	Inhaled Treprostinil in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease with Less Severe Hemodynamics: A Post hoc Analysis of the INCREASE Open Label Extension	Eric Shen	PharmD		eshen@unither.com

Industry	Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease: PHINDER Study Design and Rationale	Eric Shen	PharmD		eshen@unither.com
Industry	Efficacy of ALY688, a novel adiponectin receptor agonist, in bleomycin-induced pulmonary fibrosis mouse model	Gary Sweeney	PhD		gsweeney@yorku.ca
Industry	Antagonism of the Thromboxane-Prostanoid Receptor as a Potential Therapy for Pulmonary Fibrosis	Ingrid Anderson	PhD	CCRP	ianderson@cumberlandpharma.com
Industry	External validation of Fibrésolve, a machine-learning algorithm, to non-invasively diagnose idiopathic pulmonary fibrosis.	James Bradley	MD		jabrad07@louisville.edu
Industry	Clinical validation of an interstitial lung disease genomic classifier on a distributed diagnostic platform	james storhoff	Ph.D.		jstorhoff@hotmail.com
Industry	Preclinical Efficacy and Toxicology Studies of SRN-001, a Novel RNAi Therapeutic Candidate for Idiopathic Pulmonary Fibrosis(IPF) using SAMiRNATM Technology	June Park	PhD		June Park <junepark@sirnagen.com>
Industry	Additive effect of BI 1015550 and nintedanib in patients with idiopathic pulmonary fibrosis (IPF)	Luca Richeldi	M.D.		luca.richeldi@policlinicogemelli.it
Industry	NALBUPHINE EXTENDED-RELEASE TABLETS REDUCE COUGHING IN PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS	Toby Maher	MD	PhD	Toby.Maher@med.usc.edu
Industry	Tyvaso DPI: Drug-Device Characteristics and Patient Clinical Considerations	Manisit Das	PhD		mdas@unither.com
Industry	Inhaled Nintedanib: Predictive Sheep Model for Human Dose Selection and Tolerability Assessment	Mark Surber	Ph.D.		msurber@avalynpharma.com
Industry	Associations between L-PF questionnaire dyspnea scores and outcomes in patients with progressive fibrosing ILDs: data from the INBUILD trial	Marlies Wijsenbeek	MD		m.wijsenbeek-lourens@erasmusmc.nl
Industry	Real World Hospitalization Outcomes in Patients with Pulmonary Hypertension and Interstitial Lung Disease	Phuong Phan	PharmD	MBA	phuong.phan@jefferson.edu
Industry	Face Validity of the Preference Questionnaire for Inhaled Treprostinil	Rebecca Crawford			rcrawford@rti.org

Industry	Pursuing clinical predictors and biomarkers for progression in ILD: analysis of the Pulmonary Fibrosis Foundation (PFF) Patient Registry	Sarah Chang	MS		au.sarah@gene.com
Industry	Targeting IPF via inhalation-Delivered Peptide NPT-0025 : A Promising Therapeutic Approach	Seon In Hwang	Ph.D.		sunin0908@gmail.com
Industry	Design of trials of BI 1015550 in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis	Toby Maher	MD		Toby.Maher@med.usc.edu
Industry	Estimating the effect of nintedanib on forced vital capacity (FVC) in children and adolescents with fibrosing interstitial lung disease: extrapolation using a Bayesian borrowing approach	Toby Maher	MD		Toby.Maher@med.usc.edu
Industry	Effect of BI 1015550, a preferential phosphodiesterase 4B inhibitor, on FEV1/FVC ratio in patients with idiopathic pulmonary fibrosis (IPF)	Vincent Cottin	M.D., Ph.D.		vincent.cottin@chu-lyon.fr